The therapeutic pipeline in migraine: What does the future hold?
Authors:
Open Access
- 27 December 2025
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (3) , e00826
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War (W81XWH2110485)
- National Institutes of Health (NS120930)
This publication has 190 references indexed in Scilit:
- Meningeal CGRP‐Prolactin Interaction Evokes Female‐Specific Migraine BehaviorAnnals of Neurology, 2021
- Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysisNeurological Sciences, 2019
- The role of peripheral vasopressin 1A and oxytocin receptors on the subcutaneous vasopressin antinociceptive effectsEuropean journal of pain, 2017
- Metabotropic glutamate receptor 5: a target for migraine therapyAnnals of Clinical and Translational Neurology, 2016
- TRPM82014
- Therapeutic prospects for migraine: Can paradise be regained?Annals of Neurology, 2013
- Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in painAmino Acids, 2010
- Molecular studies of BKCa channels in intracranial arteries: presence and localizationCell and tissue research, 2008
- No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trialsAnnals of Neurology, 2000
- Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnnals of Neurology, 1988